Jim Simons
AVDL

Jim Simons’s Avadel Pharmaceuticals AVDL Stock Holding History

Jim Simons’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-273,600
Closed -$5.9M – 3251
2025
Q4 		$5.9M Sell
273,600
-282,500
-51% -$5.48M 0.01% 1206
2025
Q3 		$8.49M Buy
556,100
+302,500
+119% +$3.94M 0.01% 1172
2025
Q2 		$2.24M Sell
253,600
-87,400
-26% -$768K ﹤0.01% 2037
2025
Q1 		$2.67M Sell
341,000
-46,800
-12% -$392K ﹤0.01% 1816
2024
Q4 		$4.08M Buy
387,800
+366,300
+1,704% +$4.45M 0.01% 1580
2024
Q3 		$282K Sell
21,500
-42,896
-67% -$653K ﹤0.01% 3004
2024
Q2 		$905K Sell
64,396
-341,610
-84% -$5.57M ﹤0.01% 2379
2024
Q1 		$6.86M Sell
406,006
-219,100
-35% -$3.26M 0.01% 1209
2023
Q4 		$8.83M Sell
625,106
-113,800
-15% -$1.34M 0.01% 1011
2023
Q3 		$7.61M Buy
738,906
+46,800
+7% +$627K 0.01% 1078
2023
Q2 		$11.4M Sell
692,106
-127,648
-16% -$1.66M 0.02% 952
2023
Q1 		$7.51M Buy
819,754
+133,948
+20% +$1.1M 0.01% 1248
2022
Q4 		$4.91M Sell
685,806
-103,100
-13% -$723K 0.01% 1533
2022
Q3 		$3.95M Sell
788,906
-65,100
-8% -$358K 0.01% 1583
2022
Q2 		$2.08M Buy
854,006
+99,700
+13% +$409K ﹤0.01% 2155
2022
Q1 		$5.15M Sell
754,306
-91,500
-11% -$629K 0.01% 1570
2021
Q4 		$6.83M Sell
845,806
-7,500
-0.9% -$68.5K 0.01% 1307
2021
Q3 		$8.36M Sell
853,306
-23,200
-3% -$183K 0.01% 1138
2021
Q2 		$5.9M Sell
876,506
-52,800
-6% -$419K 0.01% 1526
2021
Q1 		$8.4M Sell
929,306
-117,000
-11% -$946K 0.01% 1304
2020
Q4 		$6.99M Sell
1,046,306
-190,377
-15% -$1.19M 0.01% 1385
2020
Q3 		$6.23M Sell
1,236,683
-101,808
-8% -$741K 0.01% 1442
2020
Q2 		$10.8M Buy
1,338,491
+432,685
+48% +$3.81M 0.01% 1171
2020
Q1 		$7.19M Buy
905,806
+51,800
+6% +$398K 0.01% 1359
2019
Q4 		$6.45M Buy
854,006
+32,000
+4% +$169K 0.01% 1708
2019
Q3 		$3.42M Buy
822,006
+19,400
+2% +$48.6K ﹤0.01% 2004
2019
Q2 		$2.32M Buy
802,606
+144,270
+22% +$248K ﹤0.01% 2252
2019
Q1 		$948K Buy
658,336
+36,836
+6% +$83.3K ﹤0.01% 2689
2018
Q4 		$1.6M Buy
621,500
+42,365
+7% +$144K ﹤0.01% 2347
2018
Q3 		$2.54M Sell
579,135
-469,935
-45% -$2.54M ﹤0.01% 2164
2018
Q2 		$6.43M Buy
1,049,070
+267,270
+34% +$1.87M 0.01% 1615
2018
Q1 		$5.7M Sell
781,800
-362,800
-32% -$3.19M 0.01% 1731
2017
Q4 		$9.39M Buy
1,144,600
+320,900
+39% +$3.01M 0.01% 1430
2017
Q3 		$8.65M Buy
823,700
+125,427
+18% +$1.2M 0.01% 1424
2017
Q2 		$7.7M Buy
698,273
+686,373
+5,768% +$6.89M 0.01% 1432
2017
Q1 		$115K Buy
+11,900
New +$119K ﹤0.01% 3069

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Jim Simons's AVDL Position: Q1 2026 in Review

Jim Simons sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 273,600 shares — an estimated $5.9M sold.

Jim Simons first reported a position in AVDL in Q1 2017 and held it in 36 quarters. The position peaked at $11.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Jim Simons reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 273,600 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.9M.
  • Jim Simons first reported a position in Avadel Pharmaceuticals in Q1 2017 and held it in 36 quarters.
  • Jim Simons's Avadel Pharmaceuticals position peaked at $11.4M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.